Related Experiment Video
Updated: Apr 23, 2026

Author Spotlight: Innovative Technique for Coronary Angiography in Marginal Donors
Published on: July 12, 2024
Everolimus prevents coronary microvasculopathy in heart transplant recipients with normal coronary angiograms: an
F Tona1, M Fedrigo1, G Famoso1
1Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Insights
Everolimus may prevent coronary microvascular remodeling in heart transplant patients, preserving coronary flow reserve (CFR). This study found hypertrophic arterioles contribute to reduced CFR, with everolimus showing a protective effect.
Area of Science:
- Cardiology
- Transplantation Immunology
- Vascular Biology
Background:
- Coronary allograft vasculopathy (CAV) affects both epicardial and microvascular coronary arteries after heart transplantation (HT).
- The impact of everolimus on coronary microvasculopathy in HT is not well understood.
- This study investigates the pathological basis of impaired coronary flow reserve (CFR) and everolimus's effect on microvascular remodeling.
Purpose of the Study:
- To assess the pathological substrate of coronary flow reserve (CFR) impairment in heart transplant (HT) patients.
- To evaluate the effect of everolimus on microvascular remodeling and CFR in HT recipients.
Main Methods:
- Studied 28 HT patients with normal coronary angiograms, divided by immunosuppression (cyclosporine + everolimus vs. cyclosporine + mycophenolate mophetil).
- Assessed microvascular remodeling and fibrosis using digital microscopy.
- Measured coronary flow velocity and calculated CFR using transthoracic Doppler echocardiography during adenosine infusion.
Main Results:
- Reduced CFR (≤2.5) correlated with increased arteriolar wall thickness and microvascular remodeling.
- Everolimus therapy was associated with significantly lower arteriolar wall thickness (15±2 vs. 32±4 μm) and higher CFR (3.2±0.5 vs. 2.8±0.9).
- Capillary density and fibrosis were similar between groups.
Conclusions:
- Hypertrophic remodeling of coronary arterioles is the pathological basis for reduced CFR in HT patients.
- Everolimus may prevent microvascular remodeling in HT recipients.
- Everolimus appears to preserve coronary flow reserve in heart transplant patients.
Background:
Coronary allograft vasculopathy (CAV) involves both epicardial vessels and coronary microcirculation. Little is known about the effect of everolimus on coronary microvasculopathy in heart transplantation (HT). The aim of our study was to assess the pathological substrate of coronary flow reserve (CFR) impairment in HT patients and the effect of everolimus on microvascular remodeling and CFR.
Methods:
We studied 28 HT patients with normal coronary angiograms (25 male, age at HT 54±10 years). Immunosuppressive regimen consisted of cyclosporine and everolimus (10 patients) or mycophenolate mophetil (18 patients). They were evaluated with digital microscopy for morphometric analysis of fibrosis and microvascular remodeling. Coronary flow velocity in the left anterior descending coronary artery was detected using transthoracic Doppler echocardiography at rest and during adenosine infusion. CFR was the ratio of hyperaemic diastolic flow velocity (DFV) to resting DFV. A CFR≤2.5 was considered abnormal and sign of coronary microvascular dysfunction.
Results:
In patients with CFR≤2.5 the thickness of the tunica media of intramyocardial arterioles was greater than in patients with CFR>2.5 (39±2 vs 17±3 μm; P=.02). Microvascular remodeling was significantly higher in patients with CFR≤2.5 (72.7±2.4 vs 50.4±8.4%; P<.007). Capillary density and fibrosis were comparable between groups (157.2±42.4 vs 175.7±42.4 capillaries/mm2; P=.3; and 6.8±5 vs 8.3±4.9%; P=.4, respectively). The thickness of the tunica media of intramyocardial arterioles was lower in patients whose therapy included everolimus (15±2 vs 32±4 μm, P=.03) and CFR was higher (3.2±0.5 vs 2.8±0.9; P=.03).
Conclusion:
The pathological substrate of reduced CFR in HT patients seems to be a hypertrophic remodeling of coronary arterioles. Everolimus appears to prevent such microvascular remodeling and preserve coronary flow reserve.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Kidney Transplant I: Introduction
Coronary Artery Disease II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Diabetic Retinopathy
Diabetic Nephropathy

